论文部分内容阅读
2012年12月,美国食品药品管理局(Food and Drug Administration,FDA)批准在美国使用水痘-带状疱疹免疫球蛋白(A Varicella-Zoster Immunoglobulin,VZIG)(加拿大温伯尼Cangene公司),进行水痘暴露后预防,针对人群为:缺乏水痘免疫力证据的、严重疾病的高危人群;以及水痘减毒活疫苗(Varicella Attenuated Live Vaccine,VarV)禁忌证的人群。VZIG是一种在新药临床申请(Investigational New Drug,IND)的扩大使用协议下已有的、也是当前美国唯一可用的VZIG制剂。VZIG是一种纯化的Ig制剂,从含有高水平抗水痘-带状疱疹病毒抗体(Antibody to Varicella-Zoster Virus,Anti-VZV)IgG的人血浆制备而得。VZIG当前获批用于VZV暴露后接种,且越快越好,理想时间为<96h(4d),以获得最大有效性。美国疾病控制与预防中心(Centers for Disease Control and Prevention,CDC)建议:于VZV暴露后<10d接种VZIG,同样越快越好。美国CDC也
In December 2012, the US Food and Drug Administration (FDA) approved the use of Varicella-Zoster Immunoglobulin (VZIG) in the United States (Winnipeg, Canada) for chickenpox Post-exposure prophylaxis is aimed at people at high risk of severe disease without evidence of chickenpox immunity; and those contraindicated at Varicella Attenuated Live Vaccine (VarV). VZIG is an existing VZIG formulation available under the Expanded Use Agreement of the Investigational New Drug (IND) and currently the only US available. VZIG is a purified Ig preparation prepared from human plasma containing high levels of Antibody to Varicella-Zoster Virus (Anti-VZV) IgG. VZIG is currently approved for VZV post-exposure vaccination, and the sooner the better, the ideal time is <96h (4d) for maximum effectiveness. The Centers for Disease Control and Prevention (CDC) recommends that vaccinating VZIG less than 10 days after VZV exposure is also faster. American CDC also